OncoMatch/Clinical Trials/NCT02830724
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Is NCT02830724 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Anti-hCD70 CAR transduced PBL and Cyclophosphamide for pancreatic cancer.
Treatment: Cyclophosphamide · Fludarabine · Aldesleukin · Anti-hCD70 CAR transduced PBL — Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18 and older diagnosed with cancer that has the CD70-expressing cancer. Design: Participants will be screened with medical history, physical exam, scans, and other tests. They may by admitted to the hospital. Leukapheresis will be performed. For this, blood is removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm. Eligible participants will have an intravenous catheter placed in their upper chest. Over several days, they will get chemotherapy drugs and the anti-CD70 cells. They will recover in the hospital. Participants will take an antibiotic for 6 months after treatment. They will repeat leukapheresis. Participants will visit the clinic every 1-3 months for the first year after treatment, every 6 months for the second year, and then as determined by their physician. Follow-up visits will take 1-2 days. At each visit, participants will have lab tests, imaging studies, and a physical exam. Throughout the study, blood will be taken and participants will have many tests to determine the size and extent of their tumor and the treatment s impact.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Renal Cell Carcinoma
Breast Carcinoma
Melanoma
Ovarian Cancer
Biomarker criteria
Required: CD70 overexpression (≥2+ CD70 positive on ≥50% of cancer cells OR ≥1+ CD70 positive on ≥75% of cancer cells by IHC)
cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on greater than or equal to 50% of cancer cells, or greater than or equal to 1+ CD70 positive on greater than or equal to 75% of cancer cells)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC > 1000/mm3 without filgrastim; WBC ≥ 2500/mm3; Platelet count ≥ 80,000/mm3; Hemoglobin > 8.0 g/dL (transfusion allowed)
Kidney function
Serum creatinine ≤ 1.6 mg/dL
Liver function
Serum ALT/AST ≤ 5.0 times ULN; total bilirubin ≤ 2.0 mg/dL (≤ 3.0 mg/dL if Gilbert's Syndrome)
ANC greater than 1000/mm(3) without the support of filgrastim; WBC greater than or equal to 2500/mm(3); Platelet count greater than or equal to 80,000/mm(3); Hemoglobin > 8.0 g/dL. Subjects may be transfused to reach this cut-off. Serum ALT/AST less than or equal to 5.0 times ULN; Serum creatinine less than or equal to 1.6 mg/dL; Total bilirubin less than or equal to 2.0 mg/dL, except in patients with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify